ES2363368T5 - Utilización de vitamina K para revertir la calcificación de los vasos sanguíneos - Google Patents

Utilización de vitamina K para revertir la calcificación de los vasos sanguíneos Download PDF

Info

Publication number
ES2363368T5
ES2363368T5 ES06076172T ES06076172T ES2363368T5 ES 2363368 T5 ES2363368 T5 ES 2363368T5 ES 06076172 T ES06076172 T ES 06076172T ES 06076172 T ES06076172 T ES 06076172T ES 2363368 T5 ES2363368 T5 ES 2363368T5
Authority
ES
Spain
Prior art keywords
vitamin
calcification
reverse
failure
cardiovascular disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06076172T
Other languages
English (en)
Other versions
ES2363368T3 (es
Inventor
Cees Vermeer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nattopharma ASA
Original Assignee
Nattopharma ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2363368(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/144,853 external-priority patent/US9364447B2/en
Application filed by Nattopharma ASA filed Critical Nattopharma ASA
Publication of ES2363368T3 publication Critical patent/ES2363368T3/es
Application granted granted Critical
Publication of ES2363368T5 publication Critical patent/ES2363368T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES06076172T 2005-06-03 2006-06-06 Utilización de vitamina K para revertir la calcificación de los vasos sanguíneos Active ES2363368T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US144853 2005-06-03
US11/144,853 US9364447B2 (en) 2002-08-30 2005-06-03 Compositions for treating or preventing cardiovascular disease

Publications (2)

Publication Number Publication Date
ES2363368T3 ES2363368T3 (es) 2011-08-02
ES2363368T5 true ES2363368T5 (es) 2015-03-02

Family

ID=36940251

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06076172T Active ES2363368T5 (es) 2005-06-03 2006-06-06 Utilización de vitamina K para revertir la calcificación de los vasos sanguíneos

Country Status (8)

Country Link
EP (1) EP1728507B2 (es)
AT (1) ATE501715T1 (es)
DE (1) DE602006020658D1 (es)
DK (1) DK1728507T4 (es)
ES (1) ES2363368T5 (es)
PL (1) PL1728507T3 (es)
PT (1) PT1728507E (es)
SI (1) SI1728507T1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220182D0 (en) 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
EP2060256A1 (en) 2007-11-16 2009-05-20 Gnosis S.p.A. Pharmaceutical and nutraceutical compositions based on menaquinols
DE102010015242A1 (de) * 2010-04-15 2011-10-20 Fresenius Medical Care Deutschland Gmbh Kombination aus Vitamin K und Nikotinamid
IT1402330B1 (it) * 2010-09-03 2013-08-30 Poli Integratore alimentare
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
US11344575B2 (en) * 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
CA3085749A1 (en) * 2017-12-14 2019-06-20 Calroy Health Sciences, Llc Methods to stabilize and reverse atherosclerotic lesions by sulfated polysaccharides
US11911349B2 (en) 2018-03-30 2024-02-27 Nattopharma As Rapidly improving vascular conditions by administering vitamin K
AU2019282420A1 (en) 2018-06-08 2021-01-07 Epizon Pharma, Inc. Methods and compositions for preventing or treating tissue calcification
KR20210018422A (ko) 2018-06-08 2021-02-17 에피존 파마 인코포레이티드 저항성칼슘형성의 예방 또는 치료를 위한 방법 및 조성물
EP3937916A1 (en) 2019-03-11 2022-01-19 Kaydence Pharma AS Rapidly improving endothelial function, reducing arterial stiffness and reversing calcification of blood vessels by administering vitamin k
CN110122866A (zh) * 2019-05-31 2019-08-16 广东双骏生物科技有限公司 一种慢性肾脏病血管钙化的特殊医学用途食品及制备方法
CN114748486A (zh) * 2022-03-25 2022-07-15 南京盛德生物科技研究院有限公司 一种含有维生素k2改善心血管钙化的药物组合物及其制备方法与应用
WO2023232643A1 (en) 2022-05-31 2023-12-07 Region Syddanmark Vitamin k2 for use in treatment of coronary artery calcification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679394B1 (en) † 1994-04-28 1998-01-14 Eisai Co., Ltd. Menatetronome derivative as antiarteriosclerotic agent
DE60128179T2 (de) 2000-05-12 2008-01-10 Nattopharma Asa Nahrungsmittel enthaltend Vitamin k2
WO2003013420A2 (en) † 2001-08-03 2003-02-20 Vitak Bv Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification
GB0220182D0 (en) † 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds

Also Published As

Publication number Publication date
DE602006020658D1 (de) 2011-04-28
ATE501715T1 (de) 2011-04-15
EP1728507A1 (en) 2006-12-06
DK1728507T4 (en) 2015-01-12
EP1728507B2 (en) 2014-11-12
PT1728507E (pt) 2011-05-27
DK1728507T3 (da) 2011-05-23
EP1728507B1 (en) 2011-03-16
PL1728507T3 (pl) 2011-09-30
SI1728507T1 (sl) 2011-07-29
ES2363368T3 (es) 2011-08-02

Similar Documents

Publication Publication Date Title
ES2363368T5 (es) Utilización de vitamina K para revertir la calcificación de los vasos sanguíneos
GB0220182D0 (en) Organic compounds
Ennabli et al. Morbidity and mortality of coronary artery surgery after the age of 70 years
DK1532269T3 (da) 1L1RL-1 som markør for kardiovaskulær sygdom
Ceyhan et al. Myocardial infarction following a bee sting
Nair et al. Heart transplant for anomalous origin of left coronary artery from pulmonary artery
EA201100143A1 (ru) Длительное лечение клинически выраженной сердечной недостаточности
Papazoglou et al. Left anterior descending coronary artery–left ventricular fistula presenting as unstable angina and syncope
Waters et al. Aortic and mitral valve replacement in a patient with osteogenesis imperfecta
Teixeira Filho et al. Right ventricular aneurysm following right ventricular infarction
Irtyuga et al. Matrix metalloproteinase activity in patients with ascending aortic aneurysm of different etiology
Ereminienė et al. Impact of advanced medical therapy for the outcome of an adult patient with Eisenmenger syndrome
POINT Case 135 aTRIaL FIBRILLaTION
Peck et al. Comparison of Exercise Hemodynamic Characteristics of Patients with Pulmonary Hypertension Based on Revised Versus Previous Definitions
Spray Hypoplastic left heart syndrome
WO2015175502A3 (en) Replacement therapy for natriuretic peptide deficiencies
Shapiro et al. BRITISH
Çağlar et al. Coexistence of Ectasia and Myocardial Bridge on the Same Coronary Artery Segment.
Franklin The pathobiology of isolated systolic hypertension
Li et al. P-406: Association of left bundle branch block with cardiovascular morbidity and mortality in hypertensive patients with left ventricle hypertrophy: the life study
Ilia et al. Right‐sided pulsus alternans in diastolic left ventricular dysfunction
Atluri et al. 779 Quantitative Pre-Operative Risk Assesment of Right Ventricular Failure during Destination Continuous Flow Left Ventricular Assist Device Implantation
Chagnon et al. Prediction of hemodynamic complications following cardiac surgery
Abe et al. Spontaneous disappearance of a saphenous vein graft pseudoaneurysm after coronary artery bypass grafting
Papadopoulos et al. Coexistence of anomalous origin of the coronary arteries and severe aortic regurgitation in Marfan syndrome